PUMA BIOTECHNOLOGY, INC. — Form SCHEDULE 13D/A
Filed October 6, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 28/100
What the filing says
Alan H. Auerbach filed an amended Schedule 13D/A on October 6, 2026, regarding beneficial ownership in PUMA Biotechnology, Inc. The filing indicates a material ownership disclosure or change in control interest reporting requirement, but the specific details of ownership percentage, share count, dollar amounts, or what changed from the prior filing are not contained in this document excerpt—only the cover page metadata is provided.
Why this rating
Amendment to ownership disclosure; specifics of ownership stake unavailable in excerpt. Without disclosed % or share count relative to PUMA's ~$145M market cap, cannot assess materiality. Routine 13D/A filing type.
See more from October 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.